← All trials
NCT03861767
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2019
- Primary completion
- Jul 31, 2020
- Completion date
- Jul 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 2000
- Arms / groups
- 10 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of PittsburghLead sponsor
- University of PittsburghOverall official - principal investigator
- University of PittsburghSponsor investigator
- Berry ConsultantsCollaborator
- University of PittsburghCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.